Hanne E H Møller1, Birgitte S Preiss1,2, Per Pedersen3, Brian Østergaard4, Mikael Frederiksen5, Niels Abildgaard2,4, Michael B Møller1,2. 1. Department of Pathology, Odense University Hospital, Odense, Denmark. 2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 3. Department of Haematology, SVS Esbjerg, Esbjerg, Denmark. 4. Department of Haematology, Odense University Hospital, Odense, Denmark. 5. Department of Haematology, SHS Aabenraa, Aabenraa, Denmark.
Abstract
OBJECTIVE: Prognostic and predictive markers in multiple myeloma are continuously explored because of the heterogeneity of the tumor biology. Myc protein is the final product from activating MYC oncogene, but the prognostic impact in multiple myeloma is not well described. METHODS: In a population-based cohort of 194 untreated, newly diagnosed patients with multiple myeloma, we assessed myc protein expression using CD138/myc immunohistochemical double stain and collected clinicopathological data. RESULTS: Cases with myc protein expression ≥40% (mycHIGH ) had a median overall survival of 11 months compared to 48 months in cases of myc protein expression <40% (mycLOW ) (P < 0.01). MycHIGH was significantly correlated to R-ISS, high proliferation index, high percentage of plasma cell in bone marrow, plasmablastic morphology, high calcium level, and abnormal karyotype. In multivariate survival analyses, mycHIGH was independently associated with inferior overall survival with a hazard ratio of 2.5. CONCLUSION: Our results indicate myc protein overexpression to be associated with advanced multiple myeloma and poor prognosis.
OBJECTIVE: Prognostic and predictive markers in multiple myeloma are continuously explored because of the heterogeneity of the tumor biology. Myc protein is the final product from activating MYC oncogene, but the prognostic impact in multiple myeloma is not well described. METHODS: In a population-based cohort of 194 untreated, newly diagnosed patients with multiple myeloma, we assessed myc protein expression using CD138/myc immunohistochemical double stain and collected clinicopathological data. RESULTS: Cases with myc protein expression ≥40% (mycHIGH ) had a median overall survival of 11 months compared to 48 months in cases of myc protein expression <40% (mycLOW ) (P < 0.01). MycHIGH was significantly correlated to R-ISS, high proliferation index, high percentage of plasma cell in bone marrow, plasmablastic morphology, high calcium level, and abnormal karyotype. In multivariate survival analyses, mycHIGH was independently associated with inferior overall survival with a hazard ratio of 2.5. CONCLUSION: Our results indicate myc protein overexpression to be associated with advanced multiple myeloma and poor prognosis.
Authors: Ellen Leich; Martin Schreder; Jordan Pischimarov; Thorsten Stühmer; Torsten Steinbrunn; Martina Rudelius; Daniela Brünnert; Manik Chatterjee; Christian Langer; Sarah Keppler; Sofia Catalina Heredia-Guerrero; Hermann Einsele; Stefan Knop; Ralf Christian Bargou; Andreas Rosenwald Journal: Blood Cancer J Date: 2021-03-04 Impact factor: 11.037
Authors: Vasilios Panagopoulos; Andrew C W Zannettino; Alanah L Bradey; Stephen Fitter; Jvaughn Duggan; Vicki Wilczek; Connor M D Williams; Emma Aj Cheney; Jacqueline E Noll; Pawanrat Tangseefa Journal: Sci Rep Date: 2022-07-30 Impact factor: 4.996
Authors: Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531